Back to search
FDAFDA · Food and drugs·Recall number D-0896-2023

PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC: N3 62541-401-10 5, NDC 62541-401-10,

Published July 19, 2023 · Recall initiated: June 23, 2023

Summary

FDA records drug Class III recall D-0896-2023, published July 19, 2023 and initiated June 23, 2023. Recalling firm: Vivus, Inc.; Status: Ongoing; Reported quantity: 4240 bottles; Lot: Lot #: 102101, Exp: 31 July 2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specifications

What to do

Voluntary: Firm initiated

Get an email if PANCREAZE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
PANCREAZE
Manufacturer
Vivus, Inc.
Distributor
Nationwide within the United States
UPC
0362541402102
Lot
Lot #: 102101, Exp: 31 July 2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC: N3 62541-401-10 5, NDC 62541-401-10, recalled?

Yes. FDA published recall D-0896-2023 on July 19, 2023. Reported hazard: Failed Stability Specifications

What should I do if I have this product?

Voluntary: Firm initiated

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: PANCREAZE. UPC: 0362541402102.